ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
The Pharma Data
APRIL 4, 2023
Both tablet strengths are available via prescription through existing specialty pharmacy networks. Food and Administration (FDA) approval for nmCRPC in February 2018, and received U.S. FDA approval for mCSPC in September 2019.To ERLEADA ® received U.S. Source link: [link]
40 
Let's personalize your content